Alnylam Pharmaceuticals annual ebitda margin
2008
2009
2010
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals EBITDA Margin Growth & History (ALNY)
Alnylam Pharmaceuticals's ebitda margin was 15.00% for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 15.00% | +20.35 pp |
| 2024 | 2024-12-31 | −5.35% | +7.13 pp |
| 2023 | 2023-12-31 | −12.48% | +58.91 pp |
| 2022 | 2022-12-31 | −71.39% | +6.91 pp |
| 2021 | 2021-12-31 | −78.30% | +82.73 pp |
| 2020 | 2020-12-31 | −161.04% | +258.65 pp |
| 2019 | 2019-12-31 | −419.68% | +647.52 pp |
| 2018 | 2018-12-31 | −1,067.21% | −525.88 pp |
| 2017 | 2017-12-31 | −541.33% | +326.92 pp |
| 2016 | 2016-12-31 | −868.25% | — |
| 2010 | 2010-12-31 | −39.11% | +2.78 pp |
| 2009 | 2009-12-31 | −41.90% | −18.90 pp |
| 2008 | 2008-12-31 | −22.99% | — |
Alnylam Pharmaceuticals quarterly ebitda margin
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.21% | +21.50 pp |
| Q1 2026 | 2026-03-31 | 26.09% | +20.62 pp |
| Q4 2025 | 2025-12-31 | 13.24% | +28.58 pp |
| Q3 2025 | 2025-09-30 | 30.57% | +43.13 pp |
| Q2 2025 | 2025-06-30 | −0.29% | −9.93 pp |
| Q1 2025 | 2025-03-31 | 5.47% | +11.52 pp |
| Q4 2024 | 2024-12-31 | −15.34% | +8.07 pp |
| Q3 2024 | 2024-09-30 | −12.56% | −42.83 pp |
| Q2 2024 | 2024-06-30 | 9.64% | +77.61 pp |
| Q1 2024 | 2024-03-31 | −6.05% | +36.46 pp |
| Q4 2023 | 2023-12-31 | −23.41% | +28.62 pp |
| Q3 2023 | 2023-09-30 | 30.27% | +123.89 pp |
| Q2 2023 | 2023-06-30 | −67.97% | +12.80 pp |
| Q1 2023 | 2023-03-31 | −42.51% | +21.85 pp |
| Q4 2022 | 2022-12-31 | −52.03% | +18.83 pp |
| Q3 2022 | 2022-09-30 | −93.62% | −3.07 pp |
| Q2 2022 | 2022-06-30 | −80.77% | −19.85 pp |
| Q1 2022 | 2022-03-31 | −64.37% | +33.43 pp |
| Q4 2021 | 2021-12-31 | −70.86% | +41.54 pp |
| Q3 2021 | 2021-09-30 | −90.54% | +81.58 pp |
| Q2 2021 | 2021-06-30 | −60.92% | +122.48 pp |
| Q1 2021 | 2021-03-31 | −97.80% | +105.82 pp |
| Q4 2020 | 2020-12-31 | −112.40% | +295.85 pp |
| Q3 2020 | 2020-09-30 | −172.13% | +130.84 pp |
| Q2 2020 | 2020-06-30 | −183.39% | +336.39 pp |
| Q1 2020 | 2020-03-31 | −203.61% | +351.89 pp |
| Q4 2019 | 2019-12-31 | −408.24% | +594.61 pp |
| Q3 2019 | 2019-09-30 | −302.96% | +11980.89 pp |
| Q2 2019 | 2019-06-30 | −519.78% | +115.91 pp |
| Q1 2019 | 2019-03-31 | −555.51% | +103.10 pp |
| Q4 2018 | 2018-12-31 | −1,002.85% | −624.23 pp |
| Q3 2018 | 2018-09-30 | −12,283.86% | −11568.99 pp |
| Q2 2018 | 2018-06-30 | −635.69% | +101.24 pp |
| Q1 2018 | 2018-03-31 | −658.60% | −112.66 pp |
| Q4 2017 | 2017-12-31 | −378.62% | — |
| Q3 2017 | 2017-09-30 | −714.86% | — |
| Q2 2017 | 2017-06-30 | −736.93% | — |
| Q1 2017 | 2017-03-31 | −545.94% | — |
| Q1 2011 | 2011-03-31 | −68.61% | −27.31 pp |
| Q4 2010 | 2010-12-31 | −52.47% | — |
| Q3 2010 | 2010-09-30 | −26.97% | +8.24 pp |
| Q2 2010 | 2010-06-30 | −39.08% | — |
| Q1 2010 | 2010-03-31 | −41.30% | — |
| Q3 2009 | 2009-09-30 | −35.21% | — |
Alnylam Pharmaceuticals ebitda margin trends
Over the last five fiscal years, Alnylam Pharmaceuticals's ebitda margin increased from −161.04% to 15.00%, a change of +176.04 percentage points. The latest reported quarter, Q2 2026, shows 21.21%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗Community posts
Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue de ...
